

Bernd Schnabl

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5402112/bernd-schnabl-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

125 papers	8,503 citations	44 h-index	91 g-index
145 ext. papers	11,577 ext. citations	9 avg, IF	6.62 L-index

#	Paper	IF	Citations
125	Interactions between the intestinal microbiome and liver diseases. <i>Gastroenterology</i> , 2014 , 146, 1513-24	13.3	596
124	Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. <i>Journal of Hepatology</i> , 2014 , 60, 1310-24	13.4	535
123	Enteric dysbiosis associated with a mouse model of alcoholic liver disease. <i>Hepatology</i> , 2011 , 53, 96-105	11.2	494
122	The gut-liver axis and the intersection with the microbiome. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018 , 15, 397-411	24.2	465
121	Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. <i>Cell Metabolism</i> , 2017 , 25, 1054-1062.e5	24.6	457
120	Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. <i>Nature Medicine</i> , 2015 , 21, 159-65	50.5	420
119	New mitochondrial DNA synthesis enables NLRP3 inflammasome activation. <i>Nature</i> , 2018 , 560, 198-203	50.4	394
118	Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. <i>Journal of Hepatology</i> , 2015 , 63, 1272-84	13.4	323
117	Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. <i>Nature</i> , 2019 , 575, 505-511	50.4	245
116	Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. <i>Journal of Hepatology</i> , 2012 , 56, 1283-92	13.4	219
115	Intestinal fungi contribute to development of alcoholic liver disease. <i>Journal of Clinical Investigation</i> , 2017 , 127, 2829-2841	15.9	209
114	Acute-on-chronic liver failure in cirrhosis. <i>Nature Reviews Disease Primers</i> , 2016 , 2, 16041	51.1	205
113	Intestinal REG3 Lectins Protect against Alcoholic Steatohepatitis by Reducing Mucosa-Associated Microbiota and Preventing Bacterial Translocation. <i>Cell Host and Microbe</i> , 2016 , 19, 227-39	23.4	197
112	Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. <i>Gastroenterology</i> , 2015 , 148, 203-214.e16	13.3	193
111	Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice. <i>Hepatology</i> , 2013 , 58, 108-19	11.2	147
110	Methods to determine intestinal permeability and bacterial translocation during liver disease. <i>Journal of Immunological Methods</i> , 2015 , 421, 44-53	2.5	142
109	Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease. <i>Gut</i> , 2019 , 68, 359-370	19.2	142

108	Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal <i>Enterococcus</i> . <i>Nature Communications</i> , 2017 , 8, 837	17.4	118
107	Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice. <i>Hepatology</i> , 2018 , 67, 2150-2166	11.2	118
106	Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice. <i>FASEB Journal</i> , 2015 , 29, 1043-55	0.9	117
105	Microbiome 101: Studying, Analyzing, and Interpreting Gut Microbiome Data for Clinicians. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 218-230	6.9	107
104	Microbiome as a therapeutic target in alcohol-related liver disease. <i>Journal of Hepatology</i> , 2019 , 70, 260-272	13.4	105
103	The gut microbiota and liver disease. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2015 , 1, 275-284	7.9	104
102	Pyroptosis by caspase11/4-gasdermin-D pathway in alcoholic hepatitis in mice and patients. <i>Hepatology</i> , 2018 , 67, 1737-1753	11.2	103
101	Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice. <i>Gut</i> , 2019 , 68, 1504-1515	19.2	100
100	Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 561-568.e1	6.9	91
99	Gut microbiota mediates diurnal variation of acetaminophen induced acute liver injury in mice. <i>Journal of Hepatology</i> , 2018 , 69, 51-59	13.4	89
98	Toll-like receptor 2-mediated intestinal injury and enteric tumor necrosis factor receptor I contribute to liver fibrosis in mice. <i>Gastroenterology</i> , 2012 , 143, 1330-1340.e1	13.3	85
97	Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. <i>Journal of Hepatology</i> , 2018 , 69, 396-405	10.4	83
96	Origin of myofibroblasts in liver fibrosis. <i>Fibrogenesis and Tissue Repair</i> , 2012 , 5, S17		79
95	Microbiota Protects Mice Against Acute Alcohol-Induced Liver Injury. <i>Alcoholism: Clinical and Experimental Research</i> , 2015 , 39, 2313-23	3.7	71
94	Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis. <i>Hepatology</i> , 2020 , 71, 522-538	11.2	71
93	Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood. <i>Hepatology</i> , 2017 , 65, 475-490	11.2	64
92	Host-microbiome interactions in alcoholic liver disease. <i>Gut and Liver</i> , 2014 , 8, 237-41	4.8	58
91	Bidirectional Communication between Liver and Gut during Alcoholic Liver Disease. <i>Seminars in Liver Disease</i> , 2016 , 36, 331-339	7.3	57

90	Indoles: metabolites produced by intestinal bacteria capable of controlling liver disease manifestation. <i>Journal of Internal Medicine</i> , 2019 , 286, 32-40	10.8	53
89	Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease. <i>British Journal of Pharmacology</i> , 2018 , 175, 469-484	8.6	53
88	Linking intestinal homeostasis and liver disease. <i>Current Opinion in Gastroenterology</i> , 2013 , 29, 264-70	3	52
87	Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. <i>American Journal of Physiology - Renal Physiology</i> , 2016 , 311, G1018-G1036	5.1	49
86	Intestinal Microbiota Mediates the Susceptibility to Polymicrobial Sepsis-Induced Liver Injury by Granisetron Generation in Mice. <i>Hepatology</i> , 2019 , 69, 1751-1767	11.2	48
85	Intestinal dysbiosis and permeability: the yin and yang in alcohol dependence and alcoholic liver disease. <i>Clinical Science</i> , 2018 , 132, 199-212	6.5	47
84	Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future. <i>Cell Host and Microbe</i> , 2020 , 28, 233-244	23.4	46
83	Gut microbiome, liver immunology, and liver diseases. <i>Cellular and Molecular Immunology</i> , 2021 , 18, 4-17	15.4	45
82	Gut microbiota, fatty liver disease, and hepatocellular carcinoma. <i>Liver Research</i> , 2018 , 2, 43-51	4.1	44
81	The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease. <i>Journal of Hepatology</i> , 2020 , 72, 391-400	13.4	41
80	Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015 , 9, 1069-76	4.2	39
79	Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. <i>Gut</i> , 2020 , 69, 764-780	19.2	39
78	Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2020 , 159, 1839-1852	13.3	37
77	Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease. <i>Cell Metabolism</i> , 2021 , 33, 21-32	24.6	37
76	Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1 α Transactivation in Steatohepatitis. <i>Cell Metabolism</i> , 2018 , 27, 339-350.e3	24.6	34
75	A TLR4/MD2 fusion protein inhibits LPS-induced pro-inflammatory signaling in hepatic stellate cells. <i>Biochemical and Biophysical Research Communications</i> , 2008 , 375, 210-4	3.4	33
74	Gut microbiota in liver disease: too much is harmful, nothing at all is not helpful either. <i>American Journal of Physiology - Renal Physiology</i> , 2019 , 316, G563-G573	5.1	32
73	Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans. <i>Gut Microbes</i> , 2020 , 12, 1782157	8.8	32

72	Fast-Track Clearance of Bacteria from the Liver. <i>Cell Host and Microbe</i> , 2016 , 20, 1-2	23.4	32
71	Insulin Resistance Increases MRI-Estimated Pancreatic Fat in Nonalcoholic Fatty Liver Disease and Normal Controls. <i>Gastroenterology Research and Practice</i> , 2013 , 2013, 498296	2	32
70	Intestinal Virome in Patients With Alcoholic Hepatitis. <i>Hepatology</i> , 2020 , 72, 2182-2196	11.2	29
69	Deficiency of intestinal mucin-2 protects mice from diet-induced fatty liver disease and obesity. <i>American Journal of Physiology - Renal Physiology</i> , 2016 , 310, G310-22	5.1	29
68	Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma. <i>Cancer Discovery</i> , 2021 , 11, 1248-1267	24.4	29
67	β-Hydroxybutyrate protects from alcohol-induced liver injury via a Hcar2-cAMP dependent pathway. <i>Journal of Hepatology</i> , 2018 , 69, 687-696	13.4	25
66	Weight Loss Decreases Magnetic Resonance Elastography Estimated Liver Stiffness in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 463-464	6.9	24
65	Changes in the fecal bacterial microbiota associated with disease severity in alcoholic hepatitis patients. <i>Gut Microbes</i> , 2020 , 12, 1785251	8.8	23
64	The microbiota in cirrhosis and its role in hepatic decompensation. <i>Journal of Hepatology</i> , 2021 , 75 Suppl 1, S67-S81	13.4	23
63	Targeting the gut-liver-immune axis to treat cirrhosis. <i>Gut</i> , 2021 , 70, 982-994	19.2	23
62	Intestinal and hepatic microbiota changes associated with chronic ethanol administration in mice. <i>Gut Microbes</i> , 2020 , 11, 265-275	8.8	22
61	Complex Network of NKT Cell Subsets Controls Immune Homeostasis in Liver and Gut. <i>Frontiers in Immunology</i> , 2018 , 9, 2082	8.4	22
60	Antimicrobial proteins: intestinal guards to protect against liver disease. <i>Journal of Gastroenterology</i> , 2019 , 54, 209-217	6.9	21
59	Role of the intestinal microbiome in liver fibrosis development and new treatment strategies. <i>Translational Research</i> , 2019 , 209, 22-38	11	18
58	Cytolysin-positive <i>Enterococcus faecalis</i> is not increased in patients with non-alcoholic steatohepatitis. <i>Liver International</i> , 2020 , 40, 860-865	7.9	18
57	Immunoglobulin A and liver diseases. <i>Journal of Gastroenterology</i> , 2018 , 53, 691-700	6.9	18
56	Nod2 deficiency protects mice from cholestatic liver disease by increasing renal excretion of bile acids. <i>Journal of Hepatology</i> , 2014 , 60, 1259-67	13.4	18
55	Serum and Fecal Oxylipins in Patients with Alcohol-Related Liver Disease. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 1878-1892	4	16

54	Genetic Loss of Immunoglobulin A Does Not Influence Development of Alcoholic Steatohepatitis in Mice. <i>Alcoholism: Clinical and Experimental Research</i> , 2016 , 40, 2604-2613	3.7	16
53	High Protein Intake Is Associated With Histological Disease Activity in Patients With NAFLD. <i>Hepatology Communications</i> , 2020 , 4, 681-695	6	16
52	Intestinal iNKT cells migrate to liver and contribute to hepatocyte apoptosis during alcoholic liver disease. <i>American Journal of Physiology - Renal Physiology</i> , 2019 , 316, G585-G597	5.1	14
51	Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know?. <i>Physiology</i> , 2020 , 35, 261-274	9.8	14
50	Gut dysbiosis as a driver in alcohol-induced liver injury. <i>JHEP Reports</i> , 2021 , 3, 100220	10.3	12
49	Risk factors for progression of and treatment options for NAFLD in children. <i>Clinical Liver Disease</i> , 2018 , 11, 11-15	2.2	11
48	What is the potential role of antifibrotic agents for the treatment of liver disease?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2008 , 5, 496-7		11
47	From intestinal dysbiosis to alcohol-associated liver disease. <i>Clinical and Molecular Hepatology</i> , 2020 , 26, 595-605	6.9	11
46	An Introduction to Next Generation Sequencing Bioinformatic Analysis in Gut Microbiome Studies. <i>Biomolecules</i> , 2021 , 11,	5.9	11
45	YIPF6 controls sorting of FGF21 into COPII vesicles and promotes obesity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 15184-15193	11.5	10
44	Multicenter Analysis of Liver Injury Patterns and Mortality in COVID-19. <i>Frontiers in Medicine</i> , 2020 , 7, 584342	4.9	10
43	The gut mycobiome: a novel player in chronic liver diseases. <i>Journal of Gastroenterology</i> , 2021 , 56, 1-11	6.9	9
42	Functional Microbiomics Reveals Alterations of the Gut Microbiome and Host Co-Metabolism in Patients With Alcoholic Hepatitis. <i>Hepatology Communications</i> , 2020 , 4, 1168-1182	6	8
41	Microbiota and Alcoholic Liver Disease. <i>Alcoholism: Clinical and Experimental Research</i> , 2016 , 40, 1791-2	3.7	8
40	Intestinal virome and therapeutic potential of bacteriophages in liver disease. <i>Journal of Hepatology</i> , 2021 , 75, 1465-1475	13.4	7
39	Alcoholic-Hepatitis, Links to Brain and Microbiome: Mechanisms, Clinical and Experimental Research. <i>Biomedicines</i> , 2020 , 8,	4.8	6
38	Transcriptomic Profiling Identifies Novel Hepatic and Intestinal Genes Following Chronic Plus Binge Ethanol Feeding in Mice. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 3592-3604	4	6
37	Persistent SARS-CoV-2 RNA Positive in Feces but Negative in Breastmilk: A Case Report of COVID-19 in a Breastfeeding Patient. <i>Frontiers in Medicine</i> , 2020 , 7, 562700	4.9	6

36	The selective PPAR-delta agonist seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in mice. <i>Translational Research</i> , 2021 , 227, 1-14	11	6
35	Dynamic Changes of the Fungal Microbiome in Alcohol Use Disorder. <i>Frontiers in Physiology</i> , 2021 , 12, 699253	4.6	6
34	Functional Microbial Responses to Alcohol Abstinence in Patients With Alcohol Use Disorder. <i>Frontiers in Physiology</i> , 2020 , 11, 370	4.6	5
33	Deficiency of Intestinal α -2-Fucosylation Exacerbates Ethanol-Induced Liver Disease in Mice. <i>Alcoholism: Clinical and Experimental Research</i> , 2020 , 44, 1842-1851	3.7	5
32	Staging of fibrosis in experimental non-alcoholic steatohepatitis by quantitative molecular imaging in rat models. <i>Nuclear Medicine and Biology</i> , 2016 , 43, 179-87	2.1	5
31	Liver capsule: Mechanisms of alcoholic hepatitis. <i>Hepatology</i> , 2016 , 64, 276	11.2	5
30	Microbial Products and Metabolites Contributing to Alcohol-Related Liver Disease. <i>Molecular Nutrition and Food Research</i> , 2021 , 65, e2000023	5.9	5
29	Differential Activation of Unconventional T Cells, Including iNKT Cells, in Alcohol-Related Liver Disease. <i>Alcoholism: Clinical and Experimental Research</i> , 2020 , 44, 1061-1074	3.7	4
28	Does the Intestinal Microbiota Explain Differences in the Epidemiology of Liver Disease between East and West?. <i>Inflammatory Intestinal Diseases</i> , 2016 , 1, 3-8	2.5	3
27	Microbiome of the Aerodigestive Tract in Health and Esophageal Disease. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 12-18	4	3
26	Fungi-Bacteria Correlation in Alcoholic Hepatitis Patients. <i>Toxins</i> , 2021 , 13,	4.9	3
25	Trajectory of Serum Bilirubin Predicts Spontaneous Recovery in a Real-World Cohort of Patients With Alcoholic Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	3
24	CRlg on liver macrophages clears pathobionts and protects against alcoholic liver disease. <i>Nature Communications</i> , 2021 , 12, 7172	17.4	3
23	Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice.. <i>Hepatology International</i> , 2022 , 1	8.8	2
22	Tumor necrosis factor alpha receptor 1 deficiency in hepatocytes does not protect from non-alcoholic steatohepatitis, but attenuates insulin resistance in mice. <i>World Journal of Gastroenterology</i> , 2020 , 26, 4933-4944	5.6	2
21	Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy-proven non-alcoholic fatty liver disease. <i>Liver International</i> , 2021 , 41, 1576-1591	7.9	2
20	Serum Acylcarnitines Associated with High Short-Term Mortality in Patients with Alcoholic Hepatitis. <i>Biomolecules</i> , 2021 , 11,	5.9	2
19	Aryl Hydrocarbon Receptor Deficiency in Intestinal Epithelial Cells Aggravates Alcohol-Related Liver Disease. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021 , 13, 233-256	7.9	2

18	Intestinal α -2-Fucosylation Contributes to Obesity and Steatohepatitis in Mice. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021 , 12, 293-320	7.9	2
17	ROR γ phosphorylation protects against T β cell-mediated inflammation.. <i>Cell Reports</i> , 2022 , 38, 110520	10.6	2
16	Promises of microbiome-based therapies.. <i>Journal of Hepatology</i> , 2022 , 76, 1379-1391	13.4	2
15	Host Factors in Dysregulation of the Gut Barrier Function during Alcohol-Associated Liver Disease. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
14	Bacteriophages and their potential for treatment of gastrointestinal diseases. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 ,	24.2	1
13	A Novel Mouse Model of Acute-on-Chronic Cholestatic Alcoholic Liver Disease: A Systems Biology Comparison With Human Alcoholic Hepatitis. <i>Alcoholism: Clinical and Experimental Research</i> , 2020 , 44, 87-101	3.7	1
12	Skin wound closure delay in metabolic syndrome correlates with SCF deficiency in keratinocytes. <i>Scientific Reports</i> , 2020 , 10, 21732	4.9	1
11	A semiparametric model for between-subject attributes: Applications to beta-diversity of microbiome data. <i>Biometrics</i> , 2021 ,	1.8	1
10	Colesevelam Reduces Ethanol-Induced Liver Steatosis in Humanized Gnotobiotic Mice. <i>Cells</i> , 2021 , 10,	7.9	1
9	Targeting pathobionts for the treatment of alcohol-associated liver disease. <i>Liver International</i> , 2021 , 41, 239-240	7.9	1
8	Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021 , 12, 891-920	7.9	1
7	Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA-AH).. <i>Liver International</i> , 2022 ,	7.9	1
6	Lipidomics for the Prediction of Progressive Liver Disease in Patients with Alcohol Use Disorder. <i>Metabolites</i> , 2022 , 12, 433	5.6	1
5	Liver specific, systemic and genetic contributors to alcohol-related liver disease progression.. <i>Zeitschrift Fur Gastroenterologie</i> , 2022 , 60, 36-44	1.6	0
4	New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease. <i>Seminars in Liver Disease</i> , 2021 , 41, 87-102	7.3	0
3	Fibroblast growth factor inducible 14 as potential target in patients with alcoholic hepatitis. <i>Gut</i> , 2013 , 62, 335-6	19.2	
2	Update on the Role of the Gut Microbiota on Alcohol-Associated Liver Disease. <i>Gastroenterology and Hepatology</i> , 2021 , 17, 381-383	0.7	
1	Reply to: "Finding fibroblast growth factor 19 during cholestasis: Does x mark the spot?". <i>Journal of Hepatology</i> , 2018 , 69, 1400-1401	13.4	

